Literature DB >> 31958162

Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

Sanjay Dhawan1, Chirag G Patil2, Clark Chen1, Andrew S Venteicher1.   

Abstract

BACKGROUND: This is an update of the review originally published in 2011 and first updated in 2015. In most people with low-grade gliomas (LGG), the primary treatment regimen remains a combination of surgery followed by postoperative radiotherapy. However, the optimal timing of radiotherapy is controversial. It is unclear whether to use radiotherapy in the early postoperative period, or whether radiotherapy should be delayed until tumour progression occurs.
OBJECTIVES: To assess the effects of early postoperative radiotherapy versus radiotherapy delayed until tumour progression for low-grade intracranial gliomas in people who had initial biopsy or surgical resection. SEARCH
METHODS: Original searches were run up to September 2014. An updated literature search from September 2014 through November 2019 was performed on the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 11), MEDLINE via Ovid (September 2014 to November week 2 2019), and Embase via Ovid (September 2014 to 2019 week 46) to identify trials for inclusion in this Cochrane review update. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared early versus delayed radiotherapy following biopsy or surgical resection for the treatment of people with newly diagnosed intracranial LGG (astrocytoma, oligodendroglioma, mixed oligoastrocytoma, astroblastoma, xanthoastrocytoma, or ganglioglioma). Radiotherapy may include conformal external beam radiotherapy (EBRT) with linear accelerator or cobalt-60 sources, intensity-modulated radiotherapy (IMRT), or stereotactic radiosurgery (SRS). DATA COLLECTION AND ANALYSIS: Three review authors independently assessed the trials for inclusion and risk of bias, and extracted study data. We resolved any differences between review authors by discussion. Adverse effects were also extracted from the study report. We performed meta-analyses using a random-effects model with inverse variance weighting. MAIN
RESULTS: We included one large, multi-institutional, prospective RCT, involving 311 participants; the risk of bias in this study was unclear. This study found that early postoperative radiotherapy was associated with an increase in time to progression compared to observation (and delayed radiotherapy upon disease progression) for people with LGG but did not significantly improve overall survival (OS). The median progression-free survival (PFS) was 5.3 years in the early radiotherapy group and 3.4 years in the delayed radiotherapy group (hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.45 to 0.77; P < 0.0001; 311 participants; 1 trial; low-quality evidence). The median OS in the early radiotherapy group was 7.4 years, while the delayed radiotherapy group experienced a median overall survival of 7.2 years (HR 0.97, 95% CI 0.71 to 1.33; P = 0.872; 311 participants; 1 trial; low-quality evidence). The total dose of radiotherapy given was 54 Gy; five fractions of 1.8 Gy per week were given for six weeks. Adverse effects following radiotherapy consisted of skin reactions, otitis media, mild headache, nausea, and vomiting. Rescue therapy was provided to 65% of the participants randomised to delayed radiotherapy. People in both cohorts who were free from tumour progression showed no differences in cognitive deficit, focal deficit, performance status, and headache after one year. However, participants randomised to the early radiotherapy group experienced significantly fewer seizures than participants in the delayed postoperative radiotherapy group at one year (25% versus 41%, P = 0.0329, respectively). AUTHORS'
CONCLUSIONS: Given the high risk of bias in the included study, the results of this analysis must be interpreted with caution. Early radiation therapy was associated with the following adverse effects: skin reactions, otitis media, mild headache, nausea, and vomiting. People with LGG who underwent early radiotherapy showed an increase in time to progression compared with people who were observed and had radiotherapy at the time of progression. There was no significant difference in overall survival between people who had early versus delayed radiotherapy; however, this finding may be due to the effectiveness of rescue therapy with radiation in the control arm. People who underwent early radiation had better seizure control at one year than people who underwent delayed radiation. There were no cases of radiation-induced malignant transformation of LGG. However, it remained unclear whether there were differences in memory, executive function, cognitive function, or quality of life between the two groups since these measures were not evaluated.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 31958162      PMCID: PMC6984627          DOI: 10.1002/14651858.CD009229.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  80 in total

1.  Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.

Authors:  Linda Dirven; Jaap C Reijneveld; Martin J B Taphoorn; Corneel Coens; Samy A El-Badawy; Tzahala Tzuk-Shina; Jose Bravo-Marques; Michael Back; Lukas J A Stalpers; Roger Stupp; Brigitta G Baumert; Clemens Seidel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-02-02       Impact factor: 7.038

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 3.  Advances in the management of low-grade gliomas.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

4.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Authors:  Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans
Journal:  Lancet Neurol       Date:  2009-08-07       Impact factor: 44.182

5.  Phase II trial of temozolomide in patients with progressive low-grade glioma.

Authors:  Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy N Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

Review 6.  Glioma extent of resection and its impact on patient outcome.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurosurgery       Date:  2008-04       Impact factor: 4.654

7.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

Authors:  Edward F Chang; Justin S Smith; Susan M Chang; Kathleen R Lamborn; Michael D Prados; Nicholas Butowski; Nicholas M Barbaro; Andrew T Parsa; Mitchel S Berger; Michael M McDermott
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

8.  Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic.

Authors:  David A Schomas; Nadia N Issa Laack; Ravi D Rao; Fredric B Meyer; Edward G Shaw; Brian Patrick O'Neill; Caterina Giannini; Paul D Brown
Journal:  Neuro Oncol       Date:  2008-11-18       Impact factor: 12.300

Review 9.  Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Authors:  Magali Lecavalier-Barsoum; Harvey Quon; Bassam Abdulkarim
Journal:  Cochrane Database Syst Rev       Date:  2014-05-15

10.  Citation classics in neuro-oncology: assessment of historical trends and scientific progress.

Authors:  Laureen D Hachem; Alireza Mansouri; Kyle Juraschka; Shervin Taslimi; Farhad Pirouzmand; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

View more
  7 in total

Review 1.  Late Sequelae of Radiotherapy—The Effect of Technical and Conceptual Innovations in Radiation Oncology.

Authors:  Ulrike Hoeller; Kerstin Borgmann; Michael Oertel; Uwe Haverkamp; Volker Budach; Hans Theodor Eich
Journal:  Dtsch Arztebl Int       Date:  2021-03-26       Impact factor: 5.594

Review 2.  Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.

Authors:  Shalini Sundramurthi Chelliah; Ervin Ashley Lourdes Paul; Muhamad Noor Alfarizal Kamarudin; Ishwar Parhar
Journal:  Molecules       Date:  2021-02-22       Impact factor: 4.411

3.  Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.

Authors:  Orwa Aboud; Ritu Shah; Elizabeth Vera; Eric Burton; Brett Theeler; Jing Wu; Lisa Boris; Martha Quezado; Jennifer Reyes; Kathleen Wall; Mark R Gilbert; Terri S Armstrong; Marta Penas-Prado
Journal:  CNS Oncol       Date:  2022-02-10

Review 4.  The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome-Guided Therapeutic Attitude.

Authors:  Melissa Silva; Catalina Vivancos; Hugues Duffau
Journal:  Brain Sci       Date:  2022-04-15

Review 5.  Tumor Microenvironment in Glioma Invasion.

Authors:  Sho Tamai; Toshiya Ichinose; Taishi Tsutsui; Shingo Tanaka; Farida Garaeva; Hemragul Sabit; Mitsutoshi Nakada
Journal:  Brain Sci       Date:  2022-04-15

6.  Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.

Authors:  Yanwei Liu; Shuai Liu; Guanzhang Li; Yanong Li; Li Chen; Jin Feng; Yong Yang; Tao Jiang; Xiaoguang Qiu
Journal:  Cancer       Date:  2021-11-15       Impact factor: 6.921

7.  S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma.

Authors:  Yu Zhang; Xin Yang; Xiao-Lin Zhu; Hao Bai; Zhuang-Zhuang Wang; Jun-Jie Zhang; Chun-Yan Hao; Hu-Bin Duan
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.